Equity
Share Repurchase Authorization Limit
West Pharmaceutical Services Share Repurchase Authorization Limit increased by 181718.2% to 1B in Q1 2026 compared to the prior quarter. Over 2 years (FY 2020 to FY 2024), Share Repurchase Authorization Limit shows a downward trend with a -6.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryCapital Allocation
SignalHigher is better
VolatilityModerate
First reportedQ4 2016
Last reportedQ4 2024
How to read this metric
Higher limits suggest strong cash flow and management's belief that the stock is undervalued.
Detailed definition
This is the maximum dollar value or share count authorized by the Board of Directors for the repurchase of the company's...
Peer comparison
Common among mature, cash-generative companies seeking to optimize their capital structure.
Metric ID:
share_repurchase_authorization_limitHistorical Data
4 periods
| Q4 '21 | Q1 '23 | Q4 '24 | Q1 '26 | |
|---|---|---|---|---|
| Value | 650K | 1B | 550K | 1B |
| QoQ Change | — | >999% | -99.9% | >999% |
Range550K – 1B
Share Repurchase Authorization Limit at Other Companies
Frequently Asked Questions
- What is West Pharmaceutical Services's share repurchase authorization limit?
- West Pharmaceutical Services (WST) reported share repurchase authorization limit of 1B in Q1 2026.
- What is the long-term trend for West Pharmaceutical Services's share repurchase authorization limit?
- Over 2 years (2020 to 2024), West Pharmaceutical Services's share repurchase authorization limit has grown at a -6.6% compound annual growth rate (CAGR), from 631K to 550K.
- What does share repurchase authorization limit mean?
- The maximum amount the company is allowed to spend on buying back its own stock.